![](http://photos1.blogger.com/blogger/6956/1083/200/Kenya.8.jpg)
The new facility will target the East and Central African market and is expected start operations by the end of this year.
The company intends to manufacture a wide range of pharmaceutical products, notably antibiotics, anti-tubercular, anti-malarial, cardiovascular, anti-diarrhoeal, analgesics, muscle relaxants, ARVs, cough and cold preparations.